← back to search

Celine Wilke

Novartis (Switzerland) · CH
Area of research
Pulmonary and Respiratory Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, PI3K/AKT/mTOR signaling in cancer, and Advanced Breast Cancer Therapies.
h-index
9
citations
3,842
works
25
NIH funding
primary concept
Medicine
email

Recent publications

Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
Journal of Clinical Oncology 2025cited by 1position: middledoi
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
European Urology 2024cited by 26position: middledoi
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
EClinicalMedicine 2024cited by 22position: middledoi
Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis
Blood 2023cited by 9position: middledoi
Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1 mouse model
Experimental Hematology 2022cited by 8position: middledoi
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
New England Journal of Medicine 2020cited by 845position: middledoi
Preclinical Rationale for the Use of Crizanlizumab (SEG101) in Myelofibrosis
Blood 2020cited by 4position: middledoi
Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study
Blood 2020cited by 3position: middledoi
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
New England Journal of Medicine 2019cited by 2,547position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Gèrard Socié · Institut de Psychiatrie et Neurosciences de Paris4 papers (2020–2025)Mohamad Mohty · Inserm4 papers (2020–2025)Reuven Or · Hadassah Medical Center4 papers (2020–2025)Jeff Szer · The Royal Melbourne Hospital4 papers (2020–2025)Robert Zeiser · I.C. Medical (United States)4 papers (2020–2025)Jason Butler · Royal Brisbane and Women's Hospital3 papers (2020–2025)Anirudh Prahallad · Novartis (Switzerland)3 papers (2020–2023)Nikolas von Bubnoff · Universitäres Kinderwunschzentrum Lübeck3 papers (2020–2023)Kim N. · St Petersburg University2 papers (2024–2024)Ken Herrmann · Indiana University – Purdue University Indianapolis2 papers (2024–2024) · 2 papers (2020–2022)Scott T. Tagawa · Cornell University2 papers (2024–2024)Karim Fizazi · Institut Gustave Roussy2 papers (2024–2024)Tsila Zuckerman · Rambam Health Care Campus2 papers (2020–2020)Maria Zingariello · Università Campus Bio-Medico2 papers (2020–2022)Bernd J. Krause · University of Rostock2 papers (2024–2024)Kambiz Rahbar · Indiana University – Purdue University Indianapolis2 papers (2024–2024) · 2 papers (2020–2025) · 2 papers (2020–2025) · 2 papers (2020–2025)